Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, U6 small nuclear 465, pseudogene (RNU6-465P)** is a non-coding RNA classified as a pseudogene derived from the highly conserved U6 small nuclear RNA sequence family[4][5]. U6 snRNA is a critical part of the spliceosome, which catalyzes the removal of introns from pre-mRNA in eukaryotes; however, RNU6-465P itself is a processed pseudogene and does not encode a functional RNA product or protein[1][3][5]. Pseudogenes like RNU6-465P arise from retrotransposition or duplication events and generally do not possess biological function, though they serve as genomic evidence of historical gene duplication or retrotranspositional activity[5]. There are no known drug interactions, disease associations, or therapeutic applications for RNU6-465P, and it is not considered a therapeutic or biological target[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 465, pseudogene (RNU6-465P).